drugset / Trial / NCT07179913

The Improvement of Low-dose Esketamine on Postoperative Depression in Patients Undergoing Bariatric Surgery With Preoperative Depression

NCT07179913

Phase 4 Active not recruiting 40 enrolled The First Hospital of Jilin University
RandomizedParallel-groupTriple-blindOther

Summary

The aim of this study is to observe the antidepressant effect of low-dose esketamine in obese patients with preoperative depression and seeking bariatric surgery. We speculate that intraoperative infusion and the addition of a small dose of esketamine to the postoperative analgesic pump can help reduce the proportion of patients with depression after surgery, and may further improve postoperative recovery, reduce the use of postoperative opioids, shorten postoperative hospital stay, and improve postoperative quality of life of patients.

Timeline

Start
2026-05-01
Primary completion
2026-11-20
Completion
2026-11-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexmedetomidine Other / unclassified 0.5 ug/kg Intravenous
Subject Esketamine Other / unclassified 0.25 mg/kg Intravenous

Indications